Q1/2024 3/31/2024 EPS -0.480 ZacksConsensus -0.300 ActVsEst (0.180) - Miss
Akoya BioSciences, Inc. (AKYA)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions [Yahoo! Finance]Yahoo! Finance
- Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment DecisionsGlobeNewswire
- Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone [Yahoo! Finance]Yahoo! Finance
- Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry MilestoneGlobeNewswire
- Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
AKYA
Earnings
- 11/14/24 - Miss
AKYA
Sec Filings
- 12/13/24 - Form 8-K
- 11/21/24 - Form 4
- 11/21/24 - Form 4
- AKYA's page on the SEC website